Loading...
•
Jun 30, 2021
Generation Bio Q2 2021 Earnings Report
Reported business highlights and financial results for the second quarter of 2021.
Key Takeaways
Generation Bio reported a net loss of $30.8 million for the second quarter of 2021. The company is transitioning its portfolio to a next-generation rapid enzymatic manufacturing process and signed a lease to build a state-of-the-art cGMP facility.
Transitioning portfolio to next-generation rapid enzymatic manufacturing process.
Signed a lease agreement to build a state-of-the-art cGMP facility.
Cash, cash equivalents and marketable securities were $425.2 million as of June 30, 2021.
Expect factor VIII expression data with ceDNA produced using RES in non-human primates for hemophilia A program by year-end.